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Purpose: Adults presenting with Borderline Personality Disorder (BPD) score poorly on 
measures of Health Related Quality of Life (HRQoL).  Little is known about HRQoL in 
adolescents with BPD type presentations and how treatment impacts quality of life.  Our 
primary aim was to use routinely collected quality-of-life outcome measures pre and post-
treatment in Dialectical Behaviour Therapy (DBT) for adolescents to address this gap. 
Secondary aims were to benchmark these data against EuroQol 5 dimensions (EQ-5D TM) 
outcomes for clients treated in clinical trials and to assess the potential of the EQ-5D™ as a 
benchmarking tool.  
Method: Four adolescent DBT teams, routinely collecting outcome data using a 
pseudonymised secure web-based system, supplied data from consecutive discharges. 
Results: Young people in the DBT programmes (n=43) had severely impaired HRQoL scores 
that were lower at programme admission than those reported in published studies using the 
EQ-5D™ in adults with a BPD diagnosis and in one study of adolescents treated for 
depression. 40% of adolescents treated achieved Reliable Clinical Change. HRQoL improved 
between admission and discharge with a large effect size.  These results were not statistically 
significant when clustering in programme outcomes were accounted for.  
Conclusion: Young people treated in NHS DBT programmes for BPD type presentations had 
poorer HRQoL than adults with a BPD diagnosis and adolescents with depression treated in 
published clinical trials. The EQ-5D™ detected reliable change in this group of adolescents. 
Programme outcome clustering suggests that both the measure and the web-based monitoring 
system provide a mechanism for benchmarking clinical programmes.  
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Whilst borderline personality disorder (BPD) is most commonly diagnosed in adults, more 
recently clinicians and researchers have begun to consider the assessment and identification of 
personality disorders in adolescents [1, 2].  Studies investigating BPD traits in young people 
report that these presentations predict the presence of personality disorders in adulthood and 
are also linked to other psychiatric disorders, impaired long-term functioning and to increased 
mortality [3-5].  Currently, there are no established effective treatments for young people with 
BPD-type presentations. More typically, adolescent research has focussed on interventions for 
repeated self-harm, one of the diagnostic criteria for BPD.  A meta-analysis of psychological 
and social interventions for suicide attempts and self-harm [6] reviewing 19 trials comprising 
2176 young people concluded that the selected interventions appeared to be effective overall 
for self-harm.  Dialectical behaviour therapy (DBT) [7,8], cognitive-behavioural therapy 
(CBT) [9] and mentalization-based therapy (MBT) [10] demonstrated the largest effect-sizes; 
however, these results require independent replication.  
 
DBT is an effective treatment for BPD in adults with robust evidence from randomised 
controlled trials demonstrating significant impacts on a number of important outcomes, 
including reduced suicidal and self-harming behaviours and service utilisation [11-18].  The 
recent Cochrane Review concluded that DBT was the only psychological treatment for BPD 
with sufficient data to pool into a meta-analysis [19].  Results demonstrated moderate to large 
statistically significant effects for DBT over treatment as usual in reductions in suicidal and 
self-harm behaviours (SMD -0.54, 95% CI -0.92 to -0.16); improvements in mental health 
(SMD 0.65, 95% CI 0.07 to 1.24) and decreases in anger (SMD -0.83, 95% CI -1.43 to -0.22).  
The National Institute for Health and Care Excellence (NICE) Guidelines for the treatment 
and management of BPD recommend DBT particularly where reduction in self-harm is a 
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clinical priority.  An earlier review reported that DBT had the potential for cost-effectiveness 
[20].   
 
As a direct consequence of its success in treating suicidal and self-harm behaviours with 
adults diagnosed with BPD, DBT was adapted for the treatment of adolescents (DBT-A) 
presenting with suicidal and self-harm behaviours who were also demonstrating features of a 
developing BPD [21].  A recent RCT of the adapted form of DBT conducted in Norway 
replicated the findings of earlier studies in adult populations.  Mehlum et al. [8] randomly 
allocated 77 adolescents presenting with suicidal and self-harming behaviour with at least two 
other BPD characteristics to either DBT-A or Enhanced Treatment as Usual (ETAU).  After 
16 weeks of treatment DBT-A was significantly superior to ETAU in terms of decreases in 
self-harm behaviour and depression.  Several non-randomised studies conducted in the UK 
and elsewhere also indicate that DBT maybe a promising intervention with adolescents 
presenting with self-harm behaviour in the context of BPD [22-25].  
 
Adults diagnosed with BPD have severe impairments in Health Related Quality of Life 
(HRQoL) [26-28].  In addition to the significant personal burden of a diagnosis of BPD [29], 
clients with BPD are typically “treatment seeking” with associated high utilisation of health 
services [30-33], leading researchers and policy makers alike to highlight the importance of 
investigating and implementing clinically and cost-effective treatments for this population 
[27,9].  Establishing cost-effectiveness (specifically cost-utility analysis) requires generic 
preference based measures that can be used to calculate the cost per additional Quality-
Adjusted Life Year (QALY). QALYs are a generic measure of disease burden that includes 
both the quality and length of life and allow for comparison across conditions to help inform 
decision makers where best to invest scarce health care resources.  NICE [34] recommend the 
EuroQol 5 Dimensions (EQ-5DTM) as the most appropriate measure for health economic 
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evaluations of new technologies.  This standardised and validated self-report measure 
describes an individual’s current health status and can be used to identify changes occurring 
over time. The construct validity and test-retest reliability of the EQ-5D™ have also been 
supported [35].   
 
As the measure is generic rather than condition-specific, the EQ-5D™ provides a common 
denominator for different evaluations allowing comparison of new technologies with each 
other. Such generic measures assess broad levels of functioning in contrast to symptomatic 
measures that may address a single clinical outcome e.g. self-harm or depression. Whilst 
individual symptom measures are an important measure of clinical outcome, clinical guidance 
recommends considering broader measures of functioning and quality of life rather than 
simply symptomatic improvement [34].  Use of generic measures maybe of particular 
importance in the case of BPD where clients’ problems impinge on a wide range of health 
domains.  
 
We therefore sought to examine the routine effectiveness of DBT as delivered in the NHS, 
with a focus solely on the EQ-5D™ as the Health Related Quality of Life (HRQoL) outcome.  
Using the EQ-5D has an additional advantage above addressing functional outcomes more 
broadly; measures that enable the calculation of QALYs across a number of services will 
provide data about cost-effectiveness of DBT as delivered in routine clinical practice, and, 
subject to sufficient variation across programmes, allow for the development of a national 
benchmarking system.  Transferring evidence-based treatments established as efficacious in 
randomised-controlled clinical trials to routine clinical practice is fraught with difficulty [36].  
Only by measuring outcomes routinely in clinical settings can the effectiveness of such 
treatments be established.  Once programmes that do not deliver good clinical outcomes can 
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be identified, organisational interventions to address poor outcomes can be developed and 
implemented. 
 
The primary aim of the pilot study was to evaluate the HRQoL outcomes of adolescents 
receiving DBT in routine clinical practice.  Our secondary aim, given the absence of studies 
reporting on HRQoL in adolescents, was to compare the findings with published RCT data on 
adults with BPD and adolescents with other mental health conditions.  Finally, we wished to 






All DBT programmes (N=9) with a subscription to the DBT pseudonymised outcome 
benchmarking (DBT-POB) website at www.dbt.uk.net were invited to participate in the study.  
The pseudonoymised outcome website was developed to assist teams to collect routine 
outcome data based on the potential value of such data for implementation of DBT 
programmes [37].  To reduce the administrative burden on participating programmes and 
hopefully maximise the success of data collection, the amount of data required was kept to an 
absolute minimum using a single outcome measure, the EQ-5D™.  Consistent with keeping 
the demands on busy programmes low, only pre- and post-treatment data were required for 
entry on the website.   Programmes were asked to assess clients on the EQ-5D™ at admission 
to the programme and on discharge, regardless of whether discharge was planned or 
unplanned.  Assessing all entrants to the programme, regardless of whether they complete 
treatment or not, provides a more conservative test of the effectiveness of a treatment 
programme.  Only including data from treatment completers may overestimate the 
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effectiveness of treatment in routine practice. Pseudonyms were selected according to the 
gender of the client so number of male and female clients in the sample as a whole is known; 
otherwise no demographic data is available at the individual client level. 
 
Seven of the subscribed nine teams were working with adolescents.  A census of DBT clients 
in treatment on a specified date established that only four of these programmes were using the 
website to routinely collect data with sufficient accuracy for benchmarking purposes, namely 
that the website was reporting the correct number of clients in treatment that day. These four 
programmes consented for their data to be downloaded from the system on the predefined 
census date and for their programme data to be included in the multi-site data analysis.  All 
participating programmes had broadly similar admission criteria (ages 14-18; five or more 
BPD criteria of which one must be the recent occurrence of self-harm behaviour).  
 
All programmes had permission from their information governance officers to upload 
pseudonymised routine outcomes to the website.  Ethical Approval was sought and received 
from the Ethics Committee of the School of Psychology, Bangor University.  The Local NHS 
Research Ethics Committee was asked for an opinion on whether the study required NHS 
approval and considered that the study qualified as service evaluation.  No patient identified 




The EQ-5D™ is a generic outcome measure that asks participants to rate their current general 
health status on 5 dimensions: mobility, self-care, usual activities, pain or discomfort and 
anxiety & depression.  The participant rates each of these dimensions at one of three different 
levels (no problems, some problems or extreme problems).  The scoring system then classifies 
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the individual into one of 243 possible health states.  Each health state provides a summary of 
the participants rating of their health status on each dimension.  For example, the health state 
‘11111’ represents perfect health on all 5 dimensions – a state that 56% of the UK population 
and 70% of the Spanish population will report on any one day [38,39].  In contrast, a health 
status of ‘33333’ indicates the worst possible health status with extreme problems on all 5 
dimensions.  These scores can be transformed into a utility score that ranges between -0.59 
and 1 (with death anchored at 0 and 1 representing perfect health) by applying societal 
weights to each level that are based on the values of these health states in adult general 
population samples derived from a choice based method such as Time Trade-Off (TTO) [40].  
Currently there are no weights derived from valuations of health states by children and 
adolescents.  Negative scores indicating health states judged as ‘worse than death’ are 
possible.  The utility scores can be used to calculate QALYs.  The sole adolescent study 
utilising the EQ-5D™ provided tentative support for its use in this client group [41].   
 
Data collection and entry 
 
Each DBT team had its own protocol for administering and entering the data onto the website.  
In most cases young people scored the questionnaires themselves.  On some occasions 
clinicians completed the questionnaires on their behalf.  Proxy completion of the EQ-5D™ is 
a recognised method of data collection.  In a recent study of the EQ-5D™ with children and 
adolescents from a community study, where parents acted as proxies, high levels of 
agreement were found between the self-report and proxy versions of the EQ-5D-Y [42].  Each 
DBT team uploaded EQ-5D scores for all patients treated in their DBT programme at 
admission and discharge.  An audit on a random selection of inputs from each team was 
conducted to ensure that the data had been accurately entered into the website.  To conduct 
the audit one of the research team (LB) telephoned the DBT team and asked them to provide 
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the EQ-5D™ scores stored on paper in the clinical notes for each client for a set of randomly 
chosen patients and time points.  These scores were checked for accuracy with the data 
already entered into the website.  No inconsistencies between the data entered onto the system 
and the original paper copies of the data were detected during this audit. 
 
Data analysis strategy 
 
Utility scores at or below zero might be anticipated in clinical samples for which achieving a 
‘life worth living’ [43] remains a daily struggle.  In a sample of adolescents in treatment for 
suicidal and self-harm behaviours a measure that captures health states considered ‘worse 
than death’ displays considerable face and criterion validity; these scores were retained.  
Difference scores were calculated by subtracting EQ-5D™ utility scores on discharge from 
those at admission.   
 
In an endeavour to establish whether the change in EQ-5D™ scores represented a robust 
change at the individual level, the Reliable Change Index for the EQ-5D was calculated using 
the Jacobson method [44]. This formula takes into account the reliability of the measure and 
variance in measurement to generate a change score in excess of which we can essentially be 
95% certain that the change in score is a real (hence, reliable) change over time.  Ideally, in 
order to exclude sources of systematic error in this calculation, an estimate of test-retest 
reliability derived from a clinical sample whose clinical characteristics have not changed over 
a period of time would be preferred.  Since clinical samples are, by definition, in treatment 
and therefore on a change trajectory and the EQ-5D™ is not yet used widely in mental health 
settings, such estimates are hard to obtain.  Hurst et al. [45 Table IX], using an intraclass 
correlation coefficient (ICC) rather than Pearson correlation because of concerns about over-
estimating reliability, reported a reliability coefficient for the EQ-5D™ of 0.78 (0.6-0.96) 
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over 2 weeks in a clinical sample of 31 rheumatoid arthritis sufferers where there was no 
change in rheumatoid arthritis. More recently Sonntag and colleagues have tabulated ICCs for 
n=106 social phobics at an interval of 6 months and n=60 at 12 months [46 Table 4] anchored 
by no change on the Liebowitz Social Anxiety Scale which are all also 0.78.  In view of the 
replication of this estimate and albeit limited clinical similarities in the study populations, this 





Description of the sample 
 
On the census date, 76 sets of client data were downloaded from four programmes of which 
66 had female pseudonyms and 10 male.  Of these 76 clients, 43 (38 female and 5 male) had 
been discharged from their respective programme and 33 were still in treatment. Admission 
EQ-5D™ utility scores for the whole sample (n=76) were 0.236 (SD 0.32, range -0.594 - 
0.848). The admission EQ-5D scores of the 43 adolescents who had completed treatment 
prior to the census date were not significantly different from the 33 young people who were 
still in treatment.  [Mean admission utility score still in treatment (n=33) = 0.244, mean 
admission utility score discharged (n=43) = 0.230, t(75)=0.19, p=0.85].  Average length of 
stay of adolescents consecutively discharged from programmes (n=43) was 177 days (SD 
116, range 23-462). 
 
Comparison of Admission and Discharge HRQoL scores 
 
Admission and discharge scores for the 43 consecutive discharges in the dataset were 
compared.  Mean admission utility scores were 0.230 (SD 0.345, range -0.590 to 0.883) and 
 
 11 
mean discharge utility scores were 0.554 (SD 0.376, range -0.008 to 1.000).  Fourteen clients 
reported health states as worse than death at admission and nine at discharge (Table 1).  These 
data were not normally distributed and were tested for significance using the Wilcoxon 
signed-rank test.  Utility scores between admission and discharge were significantly different 
(z=-4.26, p<.001).   
 
Variability between DBT programmes in baseline health status on admission (p<0.001) and 
their ability to generate changes in EQ-5D scores between admission and discharge 
(p<0.0001) was apparent in the dataset.  This was indicative of clustering in the data that 
would exaggerate the significance levels in analyses if not accounted for.  An intra-
programme correlation coefficient was calculated from the difference scores (treating DBT 
programme as a random effect) and used to inflate the width of the estimated confidence 
interval for mean differences to account for between-programme variability in outcomes. 
The high-level of clustering, indicated by an ICC of 0.71, increased the variance of the 
average difference score by a factor of approximately 12 according to the exact method of 
calculation for unequal cluster sizes given by Donner, Birkett and Buck [47].  The average 
difference in EQ-5D™ utility scores of 0.32 between admission and discharge failed to attain 
statistical significance once this adjustment was made (t=1.56, p=0.13).  
 
The Reliable Change Index calculation indicated that EQ-5D™ difference scores of at least 
0.45 could be considered reliable in the present study.  Seventeen clients in the sample of 43 
(40%) experienced reliable change between admission and discharge.  The ability of clients to 
achieve change on the EQ-5D™ was constrained by an obvious ceiling effect in that over 
25% in the DBT sample had a utility score >0.55 on admission and so could not achieve a 




Comparison of HRQoL scores with other published data sets 
 
Ishak et al. [48] identified only 10 studies of psychotherapeutic interventions for BPD 
incorporating the use of HRQoL measures, of which only three report the EQ-5D™ as an 
outcome measure (McMain et al. [17] analyse the Euroqol VAS thermometer but do not 
report the EQ-5D utility scores) and, of these remaining three, only two represent unique 
datasets (van Asselt et al. [26] re-analyse the Giesen-Bloo 2006 dataset [49]).  Both are 
studies in adult BPD.  There is currently limited, but promising evidence to support the use of 
the EQ-5D instrument in CAMHS settings as a HRQoL measure [41].  
 
Baseline and discharge EQ-5D™ scores for this clinical sample of admissions are presented 
in Table 1, alongside pre-and post-intervention EQ-5D™ scores from the few available RCTs 
in mental health for comparison purposes.  As the present study is a small-uncontrolled study 
and primarily of clinical interest in relation to benchmarking outcomes across DBT 
programmes, effect sizes using Cohen’s d are also reported.   The EQ-5D™ scores at 
treatment commencement are much lower in this study than in the studies of BPD in adult 
populations (Nadort et al t (103) = 2.15, p<.05, [50]; van Asselt et al t (89) = 2.70, p<0.005 
[51]), both of which were of Schema-Focussed therapy.  The adolescents in this pilot study 
end treatment at an EQ-5D™ score average commensurate with the starting EQ-5D™ scores 
of adolescents in the RCT for depression [41] (t (241) = 0.88, p>.02, ns).  The effect size for 
this pilot study is higher than the two adult studies [50,51] but a similar size to the adolescent 
depression study [41].   
            
  
   INSERT Table 1 ABOUT HERE 






This study is the first to report on HRQoL of adolescents with BPD-type presentations in 
routine clinical practice. Participants in the DBT programmes in this study had significantly 
impaired health related quality of life (HRQoL) on admission, scoring significantly lower 
than data available from a published RCT using the EQ-5D with BPD participants [26] and 
from a study reporting on the treatment of adolescents with depression [41].  These data 
therefore support the often-expressed view of clinicians that clients in clinical services are 
more severe than those participating in clinical trials.  Indeed, this view has been highlighted 
as a barrier to the implementation of evidence-based practice [52].  
 
Alternatively the experience of BPD in adolescence compared to adulthood may have a 
particularly significant effect on HRQoL.  Typically adolescents presenting with developing 
BPD in adolescence have experienced high levels of adversity in a context of genetic 
vulnerability over many years [2]. In addition to significant mental health difficulties with 
high rates of comorbidity [53, 54], they encounter major problems at school and with familial 
relationships and friends [55-57] that persist often into adulthood even when some of the 
more impulsive behaviours may have subsided.  In clinical practice the broad ranging impact 
on almost all aspects of development is striking.  Poor HRQoL in this context is perhaps 
unsurprising.  
 
Despite the severity of impairment demonstrated in the patients treated in the DBT 
programmes, their HRQoL improved between admission and discharge with 40% of the 
sample achieving Reliable Clinical Change. This finding is particularly interesting when 
considering the fact that patients were discharged for multiple reasons – including both 
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planned (e.g. they completed the DBT programme and no longer needed DBT) and unplanned 
discharges (e.g. the patient chose to stop attending treatment).  This study reported on the 
changes between admission and discharge for all patients who had received DBT regardless 
of whether they completed the treatment programme or not.  This finding also runs counter to 
the views clinicians express [52] that increased clinical severity might prevent significant and 
reliable clinical change. 
 
Despite the change in HRQoL scores for patients in the DBT programmes, discharge scores 
remained considerably lower than the general population norm and comparable to the scores 
of adolescents commencing treatment in an RCT for depression [41]. These findings 
underscore the view, reported in the literature, that individuals with BPD have significant 
impairment of HRQoL [26-28] even following what is an effective treatment.   The results 
suggest that further research should be directed towards further enhancing clinical outcomes.  
Typically, adaptations of DBT for adolescents have shortened the programme duration from 1 
year (typical in adult services) to 16 weeks [8, 20].  The final HRQoL outcomes in this study 
would argue against this given the low level of functioning of adolescents at treatment end 
and that adolescents in this study had a longer average treatment length than that described in 
the literature [8, 21].  In the shorter forms of DBT-A adolescents entering the programme 
typically have fewer BPD symptoms (typically 2-3) whereas in the clinical programmes 
studied here inclusion criteria to the programme required 5 or more BPD criteria which may 
account for the longer treatment duration.  These results suggest that for adolescents at this 
level of severity longer treatment durations may be necessary. 
 
Not all of the programmes were equally successful in producing good HRQoL outcomes. 
When this variability was accounted for outcomes were not significantly different at treatment 
end.  The level of clustering in the dataset (ICC of 0.71) is unusually high, beyond the range 
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commonly encountered in naturally occurring biological and disease-related phenomena. 
Such variability is perhaps not uncommon in pilot data, especially with a team-based 
treatment delivered within highly variable organisational contexts. Whether the high levels of 
clustering were driven by differences in programme fidelity or therapist competence or are 
simply the artefact of small numbers of participants with a condition with highly variable 
outcomes is unknown.  Future studies with more programmes with larger numbers of teams 
and treated clients will be necessary to tease out this finding. Paradoxically, the differential 
success of the DBT programmes in producing HRQoL outcomes, with some programmes 
performing better than others, augurs well for the intended use of the website for future 
benchmarking between programmes.  
 
Whilst these findings in this pilot study are of interest, aspects of the data collection indicate 
that they should be interpreted with a significant degree of caution.  Firstly, only four out of 
seven CAMHS teams with a subscription to the website were successfully using the system to 
collect routine data.  The teams that were collecting data may have been especially motivated 
and thus potentially have been more likely to produce improved outcomes.  Resolving 
problems in routinely collecting outcomes using the system would be essential for future 
meaningful use of the system to collect national outcome data or to benchmark programmes 
systematically.  Secondly, these data were collected under routine clinical practice conditions 
and so the research team did not control data collection and entry. Each individual DBT 
programme operated their own data administration, collection and entry procedures for their 
own clinical purposes and this may have led to different protocols for data collection.  In 
some teams the proportion of EQ-5Ds completed by clinicians as a proxy, may have been 
higher and in some cases clinicians recorded the measure retrospectively, particularly in 
circumstances where patients left the programme prematurely.  Both of these practices may 
have resulted in biases in the data.  However, as all teams were collecting data in real time 
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(i.e. they were administering scores as and when patients were admitted and discharged) 
before consenting to participate in the research study, opportunities for systematic bias were 
reduced.  Secondly, the absence of any additional data on either the participants or other 
outcomes limits generalizability.  Thirdly, the absence of a control group means that change 
in the sample cannot be attributed to the treatment that they received.  The absence of a 
control group and the high-level of clustering means that these data cannot make any 
definitive statement about whether DBT is effective in adolescents with BPD treated in 
routine clinical practice. 
 
In conclusion, although further research is necessary to unpick the findings of this pilot study, 
the DBT outcome monitoring website has demonstrated its potential to collect data in routine 
practice and in real-time and thus may be a promising tool to benchmark what is gained and 
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Table 1: Comparison of EQ-5D scores across studies. 
 







Present study: n=43 
routine admissions to 
DBT programmes 
0.23   
(0.12 – 0.34) 
EQ-5D<0 
33%1 
0.55   





0.32   
(0.20 – 0.44) 
p<0.001 
1.00 
RCTs in Adults       
Nadort et al. [50] 
n=62 SFT v modified 
SFT for adult BPD 
0.44 
(0.31 – 0.56) 
0.56 




(0.02 – 0.22) 
p=0.02 
.392 
van Asselt et al. [51] 
n=48 transference v 
SFT for adult BPD 
0.50   
(0.41 – 0.59) 
0.69 




(0.09 – 0.29) 
p<0.001 
.64 
RCTs in CAMHS      
Byford et al. [41] 
n=199 CBT/SSRI v 
SSRI for adolescent 
depression  
0.50 










(not reported)  .90 
1 Includes 9 clients (21%) admitted in state 11233 whose utility remained unchanged at -0.008 
2 Relative to baseline variance which is the effect size commonly used in power calculations, Nadort et al. 
[50] calculate effect sizes relative to pooled variance (pre/post) and report a lower estimate of 0.35 
 
 
 
 
